NewAmsterdam Pharma

NewAmsterdam (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases.

The company aims to address a significant unmet need for a potent, cost-effective and convenient LDL-lowering therapy as an adjunct to statins, a class of lipid-lowering medications that are the current standard of care for high-risk CVD patients with high cholesterol.

Their therapy, obicetrapib, an oral, low-dose and once-daily CETP inhibitor, has demonstrated positive results in phase 3 clinical trials. NewAmsterdam’s partner, A. Menarini International, submitted a Marketing Authorisation Application for obicetrabib monotherapy and obicetrapib plus ezetimibe fixed-dose combination therapy to the EMA (as of August 2025).